Combination treatment of cancer with elicitor of gene product expression and gene-product targeting agent
AssigneeIntrogen Therapeutics, Inc.
InventorsJack Roth, Guido Schumacher, Sunil Chada
Life of this patent
Estimating the term…
Abstract
The present invention concerns cancer therapy employing an expression construct that affects regulation of one or more particular nucleic acid sequences that encodes a gene product to which an agent is then targeted. In specific embodiments, the present invention relates to the use of p53 gene therapy to treat cancers in combination with Erbitux™(cetuximab). Viral and non-viral gene delivery systems are disclosed.
Claims35
A method of treating a subject with cancer comprising administering to said subject:
- (a) a p53 expression construct comprising a nucleic acid segment encoding p53, said segment under the control of a promoter active in a cancer cell of said subject, said p53 expression construct expressing p53 in said cancer cell;
- and
- (b) an agent that targets the expressed product of a p53 expression construct-responsive nucleic acid sequence in said cell, whereby said expression construct and agent are provided in amounts that treat said cancer.
A method of treating a subject with cancer comprising administering to said subject, in combination,
- (a) an expression construct comprising a nucleic acid segment encoding p53, said segment under the control of a promoter active in a cancer cell of said subject, said expression construct expressing p53 in said cancer cell;
- and
- (b) cetuximab,
- whereby said expression construct and cetuximab are provided in amounts that treat said cancer.
A pharmaceutical formulation comprising (a) an expression construct comprising a nucleic acid segment encoding p53, said segment under the control of a promoter active in a cancer cell of said subject;
- and (b) an agent that targets a gene product of the nucleic acid segment.
A kit comprising, in separate containers, (a) an expression construct comprising a nucleic acid segment encoding p53, said segment under the control of a promoter active in a cancer cell of said subject;
- and (b) an agent that targets a gene product of the nucleic acid segment.
Dependencies are inferred from the claim text.